Log in

NASDAQ:NVCR - Novocure Stock Price, Forecast & News

$77.28
-2.17 (-2.73 %)
(As of 02/28/2020 01:29 AM ET)
Today's Range
$70.00
Now: $77.28
$81.98
50-Day Range
$77.28
MA: $87.73
$95.75
52-Week Range
$41.51
Now: $77.28
$98.84
Volume1.43 million shs
Average Volume910,338 shs
Market Capitalization$7.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.21 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.65 billion
Next Earnings DateN/A
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, February, 27th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.05. The medical equipment provider earned $99.23 million during the quarter, compared to analysts' expectations of $99.10 million. Novocure had a negative net margin of 8.43% and a negative return on equity of 18.45%. The firm's revenue for the quarter was up 42.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) EPS. View Novocure's Earnings History.

What guidance has Novocure issued on next quarter's earnings?

Novocure issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 equities research analysts have issued 12-month price objectives for Novocure's stock. Their forecasts range from $50.00 to $97.00. On average, they expect Novocure's share price to reach $80.33 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

News articles about NVCR stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novocure earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novocure.

Are investors shorting Novocure?

Novocure saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,110,000 shares, an increase of 5.4% from the January 15th total of 3,900,000 shares. Based on an average daily trading volume, of 906,500 shares, the short-interest ratio is presently 4.5 days. Currently, 5.2% of the shares of the company are short sold. View Novocure's Current Options Chain.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (12.31%), Baillie Gifford & Co. (8.09%), Capital World Investors (5.09%), Renaissance Technologies LLC (2.27%), State Street Corp (1.69%) and Capital International Investors (1.40%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Mitsubishi UFJ Trust & Banking Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, UBS Asset Management Americas Inc., Nicholas Investment Partners LP, Jacobs Levy Equity Management Inc. and Citigroup Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Invus Financial Advisors LLC, FMR LLC, Fiera Capital Corp, Panagora Asset Management Inc., Geode Capital Management LLC, State Street Corp and Pictet Asset Management Ltd.. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $77.28.

How big of a company is Novocure?

Novocure has a market capitalization of $7.65 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  382 (Vote Underperform)
Total Votes:  787
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel